Chuen Wen Tan1, Liam Pock Ho2, Shirin Kalimuddin3, Benjamin Pei Zhi Cherng4, Yii Ean Teh4, Siew Yee Thien4, Hei Man Wong4, Paul Jie Wen Tern4, Manju Chandran5, Jason Wai Mun Chay6, Chandramouli Nagarajan1, Rehena Sultana7, Jenny Guek Hong Low3, Heng Joo Ng8. 1. Department of Hematology, Singapore General Hospital, Singapore. 2. Department of Hematology, Singapore General Hospital, Singapore; Department of Clinical Pathology, Singapore General Hospital, Singapore; Department of Pathology, Sengkang General Hospital, Singapore. 3. Department of Infectious Diseases, Singapore General Hospital, Singapore; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. 4. Department of Infectious Diseases, Singapore General Hospital, Singapore. 5. Department of Endocrinology, Singapore General Hospital, Singapore. 6. Department of Clinical Pathology, Singapore General Hospital, Singapore; Department of Pathology, Sengkang General Hospital, Singapore. 7. Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore. 8. Department of Hematology, Singapore General Hospital, Singapore. Electronic address: ng.heng.joo@singhealth.com.sg.
Abstract
OBJECTIVES: The aim of this study was to determine clinical outcomes of older patients with coronavirus (COVID-19) who received a combination of vitamin D, magnesium, and vitamin B12 (DMB) compared with those who did not. We hypothesized that fewer patients administered this combination would require oxygen therapy, intensive care support, or a combination of both than those who did not. METHODS: This was a cohort observational study of all consecutive hospitalized patients ≥50 y of age with COVID-19 in a tertiary academic hospital. Before April 6, 2020, no patients received the (DMB) combination. After this date, patients were administered 1000 IU/d oral vitamin D3, 150 mg/d oral magnesium, and 500 mcg/d oral vitamin B12 upon admission if they did not require oxygen therapy. Primary outcome was deterioration leading to any form of oxygen therapy, intensive care support, or both. RESULTS: Between January 15 and April 15, 2020, we identified 43 consecutive patients ≥50 y of age with COVID-19. Seventeen patients received DMB before onset of primary outcome and 26 patients did not. Baseline demographic characteristics between the two groups were significantly different by age. In univariate analysis, age and hypertension had a significant influence on outcome. After adjusting for age or hypertension separately in a multivariate analysis, the intervention group retained protective significance. Fewer treated patients than controls required initiation of oxygen therapy during hospitalization (17.6 vs 61.5%, P = 0.006). DMB exposure was associated with odds ratios of 0.13 (95% confidence interval [CI], 0.03-0.59) and 0.20 (95% CI, 0.04-0.93) for oxygen therapy, intensive care support, or both on univariate and multivariate analyses, respectively. CONCLUSIONS: A vitamin D / magnesium / vitamin B12 combination in older COVID-19 patients was associated with a significant reduction in the proportion of patients with clinical deterioration requiring oxygen support, intensive care support, or both. This study supports further larger randomized controlled trials to ascertain the full benefit of this combination in ameliorating the severity of COVID-19.
OBJECTIVES: The aim of this study was to determine clinical outcomes of older patients with coronavirus (COVID-19) who received a combination of vitamin D, magnesium, and vitamin B12 (DMB) compared with those who did not. We hypothesized that fewer patients administered this combination would require oxygen therapy, intensive care support, or a combination of both than those who did not. METHODS: This was a cohort observational study of all consecutive hospitalized patients ≥50 y of age with COVID-19 in a tertiary academic hospital. Before April 6, 2020, no patients received the (DMB) combination. After this date, patients were administered 1000 IU/d oral vitamin D3, 150 mg/d oral magnesium, and 500 mcg/d oral vitamin B12 upon admission if they did not require oxygen therapy. Primary outcome was deterioration leading to any form of oxygen therapy, intensive care support, or both. RESULTS: Between January 15 and April 15, 2020, we identified 43 consecutive patients ≥50 y of age with COVID-19. Seventeen patients received DMB before onset of primary outcome and 26 patients did not. Baseline demographic characteristics between the two groups were significantly different by age. In univariate analysis, age and hypertension had a significant influence on outcome. After adjusting for age or hypertension separately in a multivariate analysis, the intervention group retained protective significance. Fewer treated patients than controls required initiation of oxygen therapy during hospitalization (17.6 vs 61.5%, P = 0.006). DMB exposure was associated with odds ratios of 0.13 (95% confidence interval [CI], 0.03-0.59) and 0.20 (95% CI, 0.04-0.93) for oxygen therapy, intensive care support, or both on univariate and multivariate analyses, respectively. CONCLUSIONS: A vitamin D / magnesium / vitamin B12 combination in older COVID-19patients was associated with a significant reduction in the proportion of patients with clinical deterioration requiring oxygen support, intensive care support, or both. This study supports further larger randomized controlled trials to ascertain the full benefit of this combination in ameliorating the severity of COVID-19.
Authors: Zahra Raisi-Estabragh; Adrian R Martineau; Elizabeth M Curtis; Rebecca J Moon; Andrea Darling; Susan Lanham-New; Kate A Ward; Cyrus Cooper; Patricia B Munroe; Steffen E Petersen; Nicholas C Harvey Journal: Aging Clin Exp Res Date: 2021-06-12 Impact factor: 3.636
Authors: Andrea Crafa; Rossella Cannarella; Rosita A Condorelli; Laura M Mongioì; Federica Barbagallo; Antonio Aversa; Sandro La Vignera; Aldo E Calogero Journal: EClinicalMedicine Date: 2021-06-18